Intelligent Monitoring in Clinical Trials

Apr 14, 2016

One of today’s big conversations in clinical research is how the conventional approach for monitoring trial conduct simply doesn’t give the best view of data to protect patient safety, comply with protocol procedures and ensure the accuracy of data collected during the conduct of a study. This conventional approach, involving periodic site visits with 100% SDV, is reactive, resource intensive and based on the retrospective detection of errors. ArisGlobal invites you to learn about the value of intelligent monitoring by downloading a complimentary white paper, “Intelligent Monitoring in Clinical Trials.” This paper describes the various types of risks involved and the importance of a framework that combines optimal monitoring strategies to support decisions about the type, intensity and frequency of monitoring a site during clinical trial conduct.
[contact-form-7 id="41" title="download the White Paper Default"]

About ArisGlobal

ArisGlobal is transforming the way today’s most successful Life Sciences companies develop breakthroughs and bring new products to market. Our end-to-end drug development technology platform, LifeSphere®, integrates our proprietary Nava® cognitive computing engine to automate all core functions of the drug development lifecycle. Designed with deep expertise and a long-term perspective that spans more than 30 years, LifeSphere® is a unified platform that boosts efficiency, ensures compliance, delivers actionable insights, and lowers total cost of ownership through multi-tenant SaaS architecture.

Headquartered in the United States, ArisGlobal has regional offices in Europe, India, Japan and China. For more updates, follow ArisGlobal on LinkedIn and Twitter.

Additional Information

Connect with ArisGlobal on LinkedIn:
Follow @Aris_Global on Twitter:


Erika Thomas
+305-726-6601 |